Navigation Links
EntreMed in Medical News

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retirement of Ronald E. Cape, Ph.D. as Director, effective June 5,...

EntreMed Reports Second Quarter 2009 Financial Results

...and fourth quarters of 2009. As of June 30, 2009, entremed had cash and short-term investments of approximately $15 million. Ms. Kathy Wehmeir-Davis, entremed Principal Accounting Officer, commented on the sec...s in the third quarter." Michael M. Tarnow, entremed Executive Chairman, further commented, "Our second...

EntreMed Reports First Quarter 2009 Financial Results

...recent realignment and continued commitment of the entremed team position the Company to pursue and advance pr... for the ENMD-2076 clinical program." About entremed EntreMed, Inc. is a clinical-stage pharmaceutic...rheumatoid arthritis. Additional information about entremed is available on the Company's web site at www.en...

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

...e Chairman, can be found on our web site at www.entremed.com . About entremed EntreMed, Inc. is a clinical-stage pharmaceutical company focusing pr...m(R) in the treatment of rheumatoid arthritis. Additional information about entremed is available on the Company's web site at www.entremed.com and in various...

EntreMed Focuses on Development of ENMD-2076

...re difficult economic times for biotech companies. entremed has made the transition to a clinical organization...red in the fourth quarter of 2008. About entremed EntreMed, Inc. is a clinical-stage pharmaceut...heumatoid arthritis. Additional information about entremed is available on the Company's web site at www.ent...

EntreMed Reports Clinical Program Progress and Company Update

...updates were given during a podium presentation by entremed President & CEO, James S. Burns, and web cast at t... the current extraordinary market conditions, entremed received notification that it will have until July...xed) in patients with non-small cell lung cancer. entremed is considering possible options for further s...

EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program

...able safety profile in preclinical studies without cardiovascular toxicity. entremed has strong intellectual property around the lead compound, ENMD-2076, and o...-2076, improving our speed and global outreach," commented Thomas H. Bliss, entremed Senior Vice President, Corporate and Business Development. Mr. Bliss contin...

EntreMed Reports First Quarter 2008 Financial Results

... and short-term investments of approximately $44 million. Dane R. Saglio, entremed Chief Financial Officer, commented on the first quarter results, "The Compa...ightly once the open Panzem(R) oncology trials conclude." James S. Burns, entremed President and CEO commented, "Going forward, we will focus our resources on...

EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference

...egulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission. CONTACT: ...

EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis

...l symptoms of the disease, including cartilage lesions, bone resorption, cellular infiltration, and pannus formation. Carolyn F. Sidor, M.D., M.B.A, entremed Vice President and Chief Medical Officer, commented, "The cross over of agents used to treat cancer into the treatment of patients with RA is well est...
EntreMed in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

... antitumor activity in preclinical models. entremed Vice President and Chief Medical Officer, Carolyn ...e pathology of hematological cancers. About entremed EntreMed, Inc. is a clinical-stage pharmaceutic...heumatoid arthritis. Additional information about entremed is available on the Company's web site at www.en...

EntreMed Presents Initial Clinical Results for ENMD-2076

...based chemotherapy in breast cancer. In addition, entremed has received an Orphan Drug Designation from the F...g candidate, a No Objection Letter was received by entremed from Health Canada permitting ENMD-2076 to be used...ther expand the clinical development of ENMD-2076, entremed has received a No Objection Letter (NOL) from the ...

EntreMed Receives New Patent for 2-Methoxyestradiol Analogs

...s of 2- methoxyestradiol (2ME2). The patent grants entremed composition-of-matter and method of use intellectu...MDLOGO ) Analogs of 2ME2 have been developed by entremed to improve metabolic stability and retain or enhan...s owned exclusively by EntreMed. James S. Burns, entremed President & Chief Executive Officer, commented, "T...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

...taxel-resistant models. To date, MKC-1 has been evaluated in over 400 patients in multiple Phase 1 and 2 clinical trials. Carolyn F. Sidor, MD, MBA, entremed Vice President and Chief Medical Officer commented on the results, "Although we did not meet our overall goal for this study, we are encouraged by the...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

...n/prnh/20010620/ENMDLOGO ) Mark R. Bray, Ph.D., entremed Vice President, Research, will give an oral presen...the special session, "New Drugs on the Horizon 2." entremed will share the podium with representatives from le...ies without cardiovascular effects. In addition, entremed scientists are scheduled for the following poster ...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

...ogical cancers later this year." James S. Burns, entremed President & Chief Executive Officer commented, "EN... Phase 1 study will trigger a milestone payment by entremed pursuant to EntreMed's acquisition of Miikana Ther... Miikana stockholders, either in cash or shares of entremed common stock. About EntreMed EntreMed, Inc. is...

EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

...effect with novel molecular imaging techniques," commented Dr. Glenn Liu. entremed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., c... other diseases, such as rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://www.entremed.com and in ...

EntreMed to Present at The New York Society of Security Analysts Industry Conference

...egulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission. CONTACT: ...

EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer

... of the cell cycle, and induce apoptosis. Carolyn F. Sidor, M.D., M.B.A., entremed Vice President and Chief Medical Officer, commented on the study, "Pancreat... other diseases, such as rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://www.entremed.com and in ...

EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model

...survival in cancer patients. Mark R. Bray, Ph.D., entremed Vice President, Research, commented on the results...ot a registered trademark of EntreMed, Inc. About entremed EntreMed, Inc. is a clinical-stage pharmaceutical...rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://...

More>>

EntreMed in Biological Technology

AssureRx Adds New CEO

... management of science and technology for pharmaceutical, diagnostic, and biotech companies. Most recently, he was president and CEO of Maryland-based entremed Inc., a public clinical-stage pharmaceuticals company developing drugs for the treatment of cancer and inflammatory diseases. Previously, he was...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...io Cancer Institute (OCI). Dr. Mark R. Bray, entremed Vice President, Research commented, "We are very e...D-2076 in cancer patients. The close proximity of entremed scientific personnel based in Toronto to our clini...ity incentives of the Orphan Drug Act. Previously entremed had received orphan drug designation for ENMD-2076...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

...vo-treated human leukemia patient samples. entremed Vice President of Research, Mark R. Bray, Ph.D., c...ene Corporation and not the Company. About entremed EntreMed, Inc. is a clinical-stage pharmac...rheumatoid arthritis. Additional information about entremed is available on the Company's web site at http://...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

...O: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) About entremed EntreMed, Inc. is a clinical-stage pharmaceutical company developing t...other diseases, such as rheumatoid arthritis. Additional information about entremed is available on the Company's web site at www.entremed.com and in various...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... primary endpoint was tumor response. The primary endpoint has been met and entremed is considering options for further studies in NSCLC patients. Options inclu...hown to promote tumor progression and decrease survival in cancer patients. entremed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., c...

EntreMed Reports Third Quarter 2008 Financial Results

....23) per share for 2007. As of September 30, 2008, entremed had cash and short-term investments of approximately $28 million. Dane R. Saglio, entremed Chief Financial Officer, commented, "We have estim...or at least the next 12 months." James S. Burns, entremed President and Chief Executive Officer, commented, ...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

...adiol) in rheumatoid arthritis (RA). The results of the study, conducted by entremed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program...itory activity on inflammation and angiogenesis." Kenneth W. Bair, Ph.D., entremed Senior Vice President, Research & Development, further commented, "These da...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

...in advanced cancer patients. Dr. Mark R. Bray, Vice President Research at entremed commented on the presentation, "The exciting work presented by Dr. Tentler ...nticipate employing these techniques in upcoming ENMD-2076 clinical trials. entremed is actively pursing development partners for this novel oral anticancer dru...

EntreMed to Present at BioPartnering Europe Conference

...ibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. entremed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development an...

EntreMed Reports Second Quarter 2008 Financial Results

... entremed to Conduct Update Call on Tuesday, August 12, 2008... and fourth quarters of 2008. As of June 30, 2008, entremed had cash and short-term investments of approximately $36 million. Dane Saglio, entremed Chief Financial Officer, commented on the second q...
Other Tags
(Date:9/30/2014)... -- In books and movies, plots involving older men chasing ... research suggests that the stereotype may be grounded in fact. ... more than 12,000 people from Finland. The researchers, led ... that women typically preferred men who were the same age ... On the other hand, men tended to have a ...
(Date:9/30/2014)... Red Bank, New Jersey (PRWEB) September 30, 2014 ... Jersey’s largest not-for-profit visiting nurse association—is pleased to announce ... officer, was honored with a NJBIZ “40 Under ... 40 of New Jersey’s most accomplished young businessmen and ... and who share a commitment to business growth, professional ...
(Date:9/30/2014)... 2014 AxoGen, Inc. (NASDAQ: AXGN), ... peripheral nerve repair market, announced the presentation of clinical ... Society for Surgery of the Hand (ASSH) 2014 Annual ... , The ASSH Best Paper Award was ... Nerve Allografts for Large Gap Nerve Discontinuities: Outcomes From ...
(Date:9/30/2014)... SOLON, OH (PRWEB) September 30, 2014 ... wiper blades sporting the iconic pink ribbon in support ... October, a popular month for businesses and non-profits to ... this worthwhile cause. , AutoTex PINK is a woman-owned ... windshield wipers. They are committed to partnering with ...
(Date:9/30/2014)... September 30, 2014 ... , From:        Hope For The ... abarnwell(at)hopeforthewarriors(dot)org , Event:        Got ... , Date:        Thursday, October 2, ... and Navy Club, 901 ...
Breaking Medicine News(10 mins):Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
(Date:9/29/2014)... article published online in Behavioral Brain Research ... brain as a result of chronic alcohol exposure that ... , Clinical assessments and research indicate that individuals with ... This can occur when people are actively drinking, when ... abstaining. , "Sleep-wake disturbances can last for months, ...
(Date:9/29/2014)... when the supercontinent of Pangea was starting to break up ... kinds of reptiles called phytosaurs and rauisuchids were at the ... the two top predators didn,t interact much as the former ... land. But those ideas are changing, thanks largely to the ... online in September in the German journal Naturwissenschaften ...
(Date:9/29/2014)... Growing Demand From Huge ... Security Concerns Continue to Propel Biometrics Market in ... is one of the fastest growing biometrics markets ... majorly in various government projects such as National ... biometrics dominates the country,s biometrics market, with other ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
Other Contents